TJBE(SZ:000695) Xin Lang Cai Jing·2025-05-23 01:33Core Viewpoint - Binhai Energy plans to acquire 100% equity of Cangzhou Xuyang Chemical through a share issuance, constituting a related party transaction due to common control by Yang Xuegang [1] Group 1: Acquisition Details - The acquisition involves Cangzhou Xuyang, which specializes in the research, production, and sales of nylon new materials, with a production capacity of 750,000 tons/year for caprolactam [1] - Cangzhou Xuyang holds a 6.1% share of the global caprolactam market, ranking second worldwide [1] - The post-investment valuation of Cangzhou Xuyang after a previous investment by Shenzhen Capital Group was 5.337 billion yuan [1] Group 2: Financial Performance - Cangzhou Xuyang's financials show a revenue of 10.311 billion yuan and a net profit of 238 million yuan for 2024, with Q1 2025 revenue at 2.412 billion yuan and net profit at 211 million yuan [2][5] - In contrast, Binhai Energy reported a revenue of 9.276 billion yuan and a net profit of 348 million yuan for 2023, with discrepancies noted in the reported net profit figures [4] Group 3: Market Conditions and Risks - The price of caprolactam has been declining, from approximately 15,000 yuan/ton at the beginning of 2024 to around 8,500 yuan/ton by May 2025, raising concerns about Cangzhou Xuyang's future profitability [9] - The industry is expected to face overcapacity issues, with a projected overcapacity rate of about 30% by 2026 due to increased production from various companies [9] - Binhai Energy's financial health is concerning, with a debt ratio rising from 45.62% in 2020 to 82.95% in Q1 2025, indicating ongoing financial struggles [8]